EXPERT VIDEOS
All video interviews from ASH 2023
Barbara F. Eichhorst describes possible approaches to improve the early detection of molecular CLL relapses, discusses venetoclax-based first-line combinations in CLL, and rates the relative efficacy and safety of different BTK inhibitors in relapsed/refractory CLL while finally sharing her personal highlights from the ASH 2023 congress.
Ramón García-Sanz gives insights into the assessment of residual disease in multiple myeloma and explains future clinical implications of these data. Moreover, he discusses in which ways the evaluation of minimal residual disease might improve the management of patients with Waldenström macroglobulinemia and shares his personal highlight from the ASH 2023 congress.
Stephan Stilgenbauer discusses the current evidence regarding the treatment of Richter transformation with modern agents and reviews the findings of the RT1 trial presented at the ASH 2023 meeting. Finally, he highlights future combinations of novel agents like adding the next-generation BCL-2 inhibitor sonrotoclax to tislelizumab plus zanubrutinib which will be investigated in the amendment of the RT1 trial or the use of the non-covalent BTK inhibitor pirtobrutinib combined with epcoritamab, a bispecific antibody, that will be in the focus of the international RT2 trial.
EXPERT VIDEOS
All video interviews from iwCLL 2023
Lydia Scarfò describes prophylactic and therapeutic measures against SARS-CoV-2 in patients with CLL, potential risk factors for mortality, seroconversion in response to vaccination and areas of research and unmet need regarding prevention and treatment of COVID-19 infections in patients with CLL and hematologic malignancies in general. Finally, she gives insights into the clinical implications of XPO1 mutations in CLL patients.
EXPERT VIDEOS
All video interviews from ESMO Lung Cancer 2023
James R. M. Black provides an overview of the potential of ctDNA in pre-operative disease stratification for early lung cancer by highlighting data from an ultra-sensitive and specific ctDNA approach. Considering the challenges of comprehensive tissue sampling and that subclones may evade tumor biopsy detection due to undersampling of metastatic sites at relapse, he finally discusses what insights ctDNA-based methods could provide into the process of metastasis spread.
Sebastian Kobold discusses the growing interest in using CAR-T cell therapy as an innovative approach to treat solid tumors in the future, as well as T cell receptor T cell therapy. Although there are still some hurdles to overcome, he discusses what remarkable developments can be expected in this field in the coming years.
Gerrina Ruiter explains the limitations of previous HER2 agents tested in solid tumors while highlighting the encouraging preliminary results of the BEAMION Lung-1 trial of zongertinib in HER2–mutant solid tumors. Lastly, she talks about the challenges of bispecific antibodies, which have recently shown robust efficacy in solid tumors.
Åslaug Helland summarizes the results from the NIPU trial combining UV1 vaccination and immunotherapy in the setting of malignant mesothelioma. Furthermore, she explains how study designs might be modified to expand treatment options in personalized medicine and explains which data could potentially be used as external comparator arms where randomized controlled trials might be unethical, or no defined standard treatment and/or too small patient groups are available.
David C. Currow highlights the encouraging results of two Phase 3 randomized trials that investigated a ghrelin antagonist to combat cachexia in NSCLC patients. He also provides an overview of the recent advancements in integrating palliative care for cancer patients, and addresses the ongoing challenges that we still face in terms of end-of-life care in everyday practice.
EXPERT VIDEOS
All video interviews from WCLC 2023
In this exclusive video interview Paul Van Schil, the current president-elect of the IASLC, provides insights into projects that will be at the focus of the IASLC in the near future and explains notable challenges regarding collaborative science and global education, which are part of the IASLC’s strategic plan. Furthermore, he shares his thoughts on improving accessibility to multidisciplinary care at the global level, the optimal first-line therapy for patients with pleural mesothelioma and his personal highlights from the WCLC 2023 congress.
Yasushi Goto discusses the effects of delta-like ligand 3 (DLL3) expression status on clinical outcomes in treated patients with small-cell lung cancer, explains in which ways DLL3 can be used as a direct target for treatment and highlights the challenges and future perspectives regarding DLL3-directed therapies in patients with SCLC. Lastly, he shares his thoughts on the optimal first-line therapy for patients with pleural mesothelioma.
EXPERT VIDEOS
All video interviews from ASCO Lung Cancer 2023
John Heymach provides an overview on the expected benefits of HER2-selective tyrosine kinase inhibitors compared to anti-HER2-antibodies while highlighting the Beamion Lung 1 data. Moreover, he talks about RET inhibitor sensitivity and resistance in lung cancer and shares which study, presented at this year’s ASCO congress, is most likely to impact standard of care treatment in NSCLC.
Marjorie G. Zauderer explains the correlations between histopathological features and genetics in the setting of malignant mesothelioma, and the potential benefit of studying therapeutically relevant subgroups of patients separately, critically discusses trails using PD-1 checkpoint inhibition in unresectable mesothelioma and once again encourages everyone to explore the poster sessions at the major conferences to interact with colleagues around the world.
EXPERT VIDEOS
All video interviews from ASCO/EHA/ICML 2023
Alessandra Tedeschi gives insights into the health-related quality of life data from the ASPEN study conducted in patients with Waldenström macroglobulinemia, discusses the notable results from the extended follow-up of the SEQUOIA study in patients with treatment-naïve chronic lymphocytic leukemia as well as the clinical activity of zanubrutinib in the setting of R/R marginal zone lymphoma while finally depicting her personal highlights from this year’s EHA congress.
Anna Schuh talks about genetic aberrations in subclones in terms of the molecular dynamics of relapse in patients with CLL, the benefits of liquid biopsies as well as the current role and future application of whole-genome sequencing in precision hematology while ultimately depicting her personal highlights from this year’s EHA congress.
Paolo Strati overviews how patient outcomes can be optimized with current therapies in relapsed or refractory diffuse large B-cell lymphoma in later lines and outlines which innovative approaches might become available in the long run for the treatment of R/R DLBCL. Finally, he explains what can be achieved today in patients with follicular lymphoma and high tumor burden and depicts his personal highlights from this year’s EHA congress.
Philipp Staber explains the role of functional drug testing in the treatment of patients with hematologic diseases, shares the rationale of the EXALT-2 trial as well as his thoughts on future developments in the field of precision medicine. Finally, he gives insights in the current research topics of the EHA SWG-Precision Hematology and their goal for the next five years.
EXPERT VIDEOS
All video interviews from ASH 2022
Shirley D’Sa discusses the results of the first clinical trial investigating checkpoint inhibition in relapsed/refractory Waldenström’s macroglobulinemia as well as other immunotherapeutic agents or combinations that might be worth investigating in this setting and explains the association of type I cryoglobulinemia with WM, IgM monoclonal gammopathy of undetermined significance or non-Hodgkin Lymphoma.
EXPERT VIDEOS
All video interviews from iwWM 2022
Roger Owen discusses whether the choice of BTK-inhibitor matters, what clinical data tell us about the long-term performance of acalabrutinib and talks about the different association of ibrutinib and zanubrutinib with efficacy in patients with Waldenström‘s Macroglobulinemia and low frequency genetic alterations while finally reflecting his highlights from the 11th International Workshop on WM especially the role of minimal residual disease as an independent predictor of patient outcomes.
Steven P. Treon explains where we are at present regarding curability of Waldenström‘s Macroglobulinemia, key questions in the management of patients with WM, genomic testing and genomically driven algorithms for the treatment of WM. Moreover, he discusses which treatments might be implemented in the future while finally summarizing his highlights from the 11th International Workshop on WM.
Jorge Castillo highlights the most relevant findings regarding chemoimmunotherapy in patients with Waldenström‘s Macroglobulinemia presented at the 11th iwWM, discusses the management of WM patients who have been exposed to covalent BTK inhibitors, explains which clinical endpoint(s) should be reached in the treatment of patients with WM and shares his thoughts on promising novel treatment approaches.
EXPERT VIDEOS
All video interviews from ESMO Solid Tumors 2022
Stacey A. Cohen explains if ctDNA can detect MRD and predict recurrence in patients with colon cancer in a real-world setting, if it should be used in daily clinical practice or as a surveillance biomarker in stage II ctDNA-negative colon cancer patients. Moreover, she depicts how the treatment of patients with colon cancer might change in the foreseeable future.
EXPERT VIDEOS
All video interviews from ESMO Lung Cancer 2022
Gérard Zalcman discusses recent findings regarding the duration of immune checkpoint inhibitor treatment in patients with NSCLC, expectations of checkpoint inhibitor therapy in the setting of unresectable malignant pleural mesothelioma and how the treatment of patients with malignant pleural mesothelioma might be further optimized based on molecular findings.
Noemi Reguart outlines if EGFR-directed treatment in the setting of advanced NSCLC should be based on T790M monitoring in clinical practice, outlines recent insights gained in the negative CANOPY-A trail using the anti-IL-1β antibody canakinumab after resection of early-stage NSCLC and summarizes the current treatment landscape in Europe with respect to small-cell lung cancer.
EXPERT VIDEOS
All video interviews from WCLC 2022
Filiz Oezkan depicts the most important factors influencing the choice of treatment in patients with PD-L1-positive NSCLC, explains how the 50 % PD-L1 threshold affects the treatment selection and explains which treatment options appear favorable in the setting of PD-L1 levels below 1 % while also taking into account possible challenges associated with biomarker testing for PD-L1 in NSCLC.
Alexander Louie explains which modes of imaging can be particularly helpful when clinicians face unique diagnostic challenges in lung cancer patients with pneumonitis after chemoradiotherapy and immunotherapy. Moreover, he summarizes what needs to be considered regarding pneumonitis treatment and highlights current and future pneumonitis research areas.
Maximilian Hochmair highlights relevant study data in the field of EGFR-mutated advanced lung cancer, novel therapies in the management of KRAS p.G12C mutation as well as MET exon 14 skipping mutations in NSCLC. He draws attention to antibody drug conjugates in the management of NSCLC patients as well as the optimal treatment sequence in the ALK-positive setting.
Federico Cappuzzo discusses the effectiveness and limitations of minimal residual disease (MRD) assessment in the detection of patients with early-stage lung cancer at low risk of relapse and highlights which clinical investigations regarding the clinical impact of MRD assessments in solid tumors are ongoing and what we can expect from them in the future.
Helmut Popper talks about the characteristics of the recently defined molecular subtypes of small-cell lung cancer (SCLC), outlines if this subtyping is suitable for therapeutic decision-making and gives an overview about potential new therapeutic targets in the field of SCLC.
Julia Rotow summarizes the achievements of EGFR tyrosine kinase inhibitors in the neoadjuvant therapy of lung cancer regarding multiple clinical outcomes, discusses if modification of the disease biology will be a feasible treatment goal in the setting of EGFR-directed neoadjuvant treatment sometime and talks about the individualization of neoadjuvant treatment of oncogene-driven lung cancer.
EXPERT VIDEOS
All video interviews from ASCO Solid Tumors 2022
Kohei Shitara talks about new promising agents in the treatment of advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma and how existing drugs can blend into these new regimens. He overviews the current state of prognostic and predictive biomarker in gastric cancer and gives an outlook on new biomarkers that are on the rise to guide therapy while finally summarizing his personal medical and scientific highlights at this year’s ASCO meeting.
Anna Spreafico depicts her personal highlights regarding immunotherapy plus chemotherapy or intensity-modulated radiotherapy for people with locally advanced nasopharyngeal cancer (NPC) at this year’s ASCO meeting, discusses if longitudinal plasma EBV DNA monitoring should be incorporated into the guidance of personalized disease management and future clinical trials, highlights the most promising agents explored in the 1L treatment of recurrent/metastatic NPC and overviews how the prognosis of those patients will evolve in the years to come.
Julien Edeline highlights which clinical trials examining combination approaches are anticipated to expand the treatment armamentarium for treatment-naïve patients with unresectable HCC and which new agents are promising in the second- and third-line treatment of advanced HCC. He gives an outlook on how the prognosis of patients with advanced HCC will evolve in the years to come while focusing on the quality of life in HCC as well as the impact of systemic treatment on it.
Ian Chau summarizes the notable efficacy and safety data obtained with nivolumab plus chemotherapy or ipilimumab versus chemo as 1L treatment for advanced ESCC in the CheckMate 648 trial and explains the role of EGFR inhibitors in the treatment of ESCC, especially in combination with radiation. He focuses on the treatment paradigm in advanced/metastatic ESCC and how it might change in the near future while also explaining the barriers to implementing precision oncology in the setting of ESCC.
EXPERT VIDEOS
All video interviews from ASCO Lung Cancer 2022
John Varlotto summarizes the insights that have been obtained based on recent studies regarding immunotherapy plus chemoradiation in patients with unresectable, locally advanced stage III non-small cell lung cancer, explains the different effect observed with pembrolizumab and nivolumab and how these results compare to existing data. He cautions against using the impressive pathologic complete response rates with neoadjuvant chemoimmunotherapy to the unresectable setting due to the lack of long-term survival rates with neo-adjuvant chemo/immunotherapy and the impressive 47.5 median overall survival noted with concurrent chemo/radiotherapy followed by consolidative durvalumab in the Pacific Trial.
Jessica Donington highlights the most promising agents currently investigated in the neoadjuvant setting in patients with resectable NSCLC, how the “intensity” of neoadjuvant treatment affects the outcomes and discusses if neoadjuvant chemo-immunotherapy is the new standard of care. She outlines which variables related to surgery itself are determinants of the success of curative surgery and which biomarkers are on the rise to guide therapy.
EXPERT VIDEOS
All video interviews from ELCC 2022
Jordi Remon outlines what needs to be considered in the context of neoadjuvant and adjuvant immunotherapy in patients with resectable lung cancer, how tyrosine kinase inhibitors can contribute to effective perioperative treatment, treatment approaches in patients with oncogene-driven lung cancer who develop brain metastases as well as in patients with CNS affection whose tumors do not harbor genetic drivers. Current challenges in selecting the best immunotherapeutic approach for the individual patient with mNSCLC and how to deal with them as well as promising potential predictive biomarkers of ICI in patients with NSCLC are highlighted, too.
Lizza Hendriks discusses how clinical trials should be adapted considering the increasing use of brain metastasis screening in lung cancer patients, the immune micro-environment of CNS metastases, the role of the treatment sequence in the management of patients with brain lesions and summarizes how patients with low PD-L1 expression, frail/elderly patients and those with actionable mutations can be addressed, followed by depicting novel biomarkers for precision immunotherapy.
Jarushka Naidoo depicts recent developments in the first-line therapy of limited-stage small cell lung cancer (SCLC), treatment options for patients with newly diagnosed extensive-stage SCLC, agents emerging for the management of patients with platinum-refractory disease, the molecular types of SCLC and how they respond to targeted therapies and ICIs and gives an overview of the greatest difficulties in the field of irAEs.
EXPERT VIDEOS
All video interviews from ASH 2021
Constantine Tam gives an overview of the results obtained by the SEQUOIA trial, the advantages and disadvantages of BTKi and BCL2i 1L therapy versus their drawbacks and explains which CLL-patients might benefit from BTK inhibitor monotherapy and who might be better off receiving combination treatment including a BTK inhibitor and how novel BCL2 inhibitors improve CLL treatment compared to the standard agent venetoclax.
Jennifer A. Woyach explains which factors need to be considered when choosing the frontline regimen for patients with early-stage CLL, how resistance to BTK inhibition can be tackled in later lines, if chemoimmunotherapy still has a role in the treatment of CLL and highlights the most interesting findings on the management of treatment-naïve CLL patients.
Paolo Ghia highlights what modern targeted agents can achieve in terms of undetectable minimal residual disease in the management of patients with CLL and important methodological recommendations to ensure correct assessment of TP53 and IGHV mutational status. He explains how the three epigenetic subgroups (m-CLL, n-CLL, i-CLL) are related, what effect a thorough immunogenetic analysis has on the risk stratification of patients with CLL and gives an overview about the most interesting findings on the management of pretreated CLL patients.
Alessandra Tedeschi depicts her personal highlights reported at ASH 2021 and explains the results obtained in treatment-naïve CLL patients with a deletion of 17p in the SEQUOIA study. The influence of age, fitness, and concomitant medications on the management and outcomes of patients with CLL treated with targeted agents, the most notable progress in B-cell malignancies over the last years and the role of BTK inhibitors in the treatment of patients with Waldenström’s macroglobulinemia are summarized, too.
EXPERT VIDEOS
All video interviews from ESMO IO 2021
Mark G. Kris outlines the potential of circulating tumor DNA along the neoadjuvant cancer treatment timeline, explains which correlations have been observed between changes in ctDNA levels and clinical outcomes in patients with early-stage lung cancer and how monitoring of ctDNA can potentially be utilized in clinical practice to guide the management of these patients, while also depicting the limitations of this approach. The excitement in the field of lung cancer about new drugs targeting KRAS in combination with immunotherapy for first line treatment in stage IV NSCLC is addressed, too.
David McDermott deals with the question if combination therapy is superior to single agent PD-1/PD-L1 blockade in the adjuvant setting, highlights tools/biomarkers for appropriate patient selection for immune checkpoint inhibitor therapies, future strategies to potentially overcome resistance to ICIs, potential new outcome parameters for clinical trials investigating ICIs and highlights the most relevant findings presented at ESMO IO 2021 in terms of immuno-oncology.
EXPERT VIDEOS
All video interviews from ESMO Solid Tumors 2021
Yelena Y. Janjigian talks about the practice-changing results obtained in the CheckMate 649 trial and how the proportion of patients with advanced gastric cancer and esophageal adenocarcinoma who receive multiple treatment lines rather than just one or two can be increased. Biomarker-targeted therapies, precision medicine approaches for advanced G/GEJ cancers, the significance of chemotherapy as well as the duration of maintenance therapy are discussed, too.
Chiara Cremolini gives an overview of strategies that might become available in the future to enhance the efficacy of immunotherapies in the setting of microsatellite-stable metastatic colorectal cancer, how to increase the proportion of patients with metastatic colorectal cancer who receive multiple treatment lines, the optimal continuum of care in 2021 in metastatic colorectal cancer and how to predict progressive disease.
Javier Cortés highlights the superiority of trastuzumab deruxtecan compared to trastuzumab emtansine in patients with HER2-positive metastatic breast cancer and the resulting future therapy algorithm, potential combinations in the management of patients with HER2-negative breast cancer and the clinical relevance of immunotherapy-based approaches in the treatment of triple-negative breast cancer.
Ian Chau depicts the most interesting trial results in the field of esophageal cancer at the ESMO 2021 congress, gives an outlook on personalized approaches in the setting of esophageal squamous-cell carcinoma with regard to biomarkers for checkpoint inhibitors as well as potential further improvements of the prognosis of patients with esophageal cancer.
Ken Kato summarizes combination regimens currently investigated in the neoadjuvant treatment of patients with esophageal cancer and outlines how immunotherapy has changed the first-line treatment standards in patients with esophageal squamous-cell carcinoma and which further developments are expected for the first-and second-line setting in the future.
EXPERT VIDEOS
All video interviews from ESMO Lung Cancer 2021
Oliver Gautschi highlights the most relevant findings presented at ESMO 2021 in terms of lung cancer, innovative treatment approaches currently tested for use in patients with unresectable malignant pleural mesothelioma, immunotherapeutic approaches in the setting of thymoma and thymic carcinoma and summarizes potential strategies for the management of RET-positive NSCLC.
Edward B. Garon relates to anticancer vaccines, an area full of promises for lung cancer patients, their potential caveats compared to other novel treatment approaches, depicts the most interesting trial results from the phase I trial of intratumoral administration of CCL21-gene modified dendritic cells combined with intravenous pembrolizumab for advanced NSCLC and explains how antibody drug conjugates like datopotamab deruxtecan, a novel TROP2-directed ADC, fit in the therapeutic landscape in the future.
Robin Cornelissen discusses new agents developed for the treatment of NSCLC patients with EGFR or HER2 exon 20 insertion mutations, the role of next-generation sequencing in clinical practice, rare drivers of lung cancer with potential interest in the future, targeted approaches in the management of lung cancer as well as prognostic markers for survival or clinical decision making before extended pleurectomy and decortication surgery in malignant pleural mesothelioma.
Natasha B. Leighl outlines recent insights gained in terms of circulating tumor DNA in patients with advanced NSCLC, the impact of liquid biopsy on the time to treatment, advantages of complementary testing, the clinical utility of plasma ctDNA testing in the context of treatment monitoring and future first-line treatment options for patients with advanced NSCLC.
EXPERT VIDEOS
All video interviews from ASCO Solid Tumors 2021
Peter R. Galle overviews the role of immunotherapy in the setting of hepatocellular carcinoma as well as biomarker-based patient selection and discusses which novel combinations of immune checkpoint inhibitors with other drug classes are most promising at present and how those novel strategies impact the treatment landscape.
Roberto Pazo-Cid outlines recent insights gained in terms of anti-PD-1 treatment in the setting of esophageal squamous cell carcinoma, talks about the practice-changing results obtained in the CheckMate 649 trial and the impact of PD-1 inhibition on the real-world prognosis of patients with gastric and esophageal adenocarcinoma as well as further developments regarding immune checkpoint inhibition.
EXPERT VIDEOS
All video interviews from ASCO/EHA/ICML 2021
Alvaro Alencar discusses which first-line treatment options might soon be established for newly diagnosed patients with mantle cell lymphoma who are not eligible for intensive therapy, what can be expected in terms of innovative approaches in the setting of R/R mantle cell lymphoma or marginal zone lymphoma and highlights the need for robust prognostic tools allowing stratification of treatment modalities.
Matthew Davids depicts the most interesting trial results in the field of CLL treatment at the EHA 2021 congress, gives an outlook on the most promising agents currently tested for use not only in elderly but also in young, fit CLL patients and talks about combinations that might be implemented as pillars of CLL treatment based on current trials.
Wojciech Jurczak gives an overview of the advantages of new BTK inhibitors, the results of the ALPINE trial comparing zanubrutinib with ibrutinib in patients with relapsed/refractory CLL/SLL and talks about which new developments can be expected in the field of innovative BTK inhibitors in the treatment of CLL and other indications.
Carol Moreno highlights the CLL study results from EHA and ICML, enlarges on fixed-duration regimens in CLL treatment, the importance of long-term follow-up findings obtained in important trials such as CLL14 and ELEVATE-TN as well as data from the ALPINE and ELEVATE-RR studies and shares her thoughts on the role of new agents such as zanubrutinib in the overall treatment landscape.
Anthony Mato talks about the study highlights presented at EHA and ICML, innovative treatment approaches currently tested for use in CLL that appear most promising and explains how the prognosis of CLL patients might change due to new therapies in the years to come and summarizes potential strategies to prevent and overcome resistance to targeted therapies.
EXPERT VIDEOS
All video interviews from ASCO Lung Cancer 2021
Martin Reck compares the combination of novel immune checkpoint inhibitors with other drug classes to monotherapy in terms of efficacy and tolerability, discusses the role of biomarkers and the tumor microenvironment in terms of treatment decision and focuses on the potential predictive value of immune-related adverse events.
David T. Cooke talks about health equity and health disparities relating to lung cancer management in the western world. He explains which factors based on ethnicity are likely to affect outcomes of lung cancer patients and how health disparities might be tackled in the long run at the public health level.
Donald R. Harvey discusses lung cancer from the point of view of clinical pharmacology, targets in the area of antibody-drug conjugates, the role of proteolysis targeting chimeras (PROTACs) in the treatment landscape, highlights mechanisms of resistance to small molecule inhibitors and draws attention to clinical trial design to better meet the demands of modern drug development.
Ferdinandos Skoulidis summarizes why the development of KRASG12C targeted therapies failed in the past, relates to new developments in the field of KRASG12C inhibition especially sotorasib and discusses the impact of co-mutations on personalized anticancer therapy.
Luis G. Paz-Ares explains which notable developments are taking place in the field of small-cell lung cancer with respect to new targets and targeted agents, how chemotherapeutic standards will change in the management of patients with small-cell lung cancer and highlights the most relevant findings presented at ASCO 2021 in terms of targeted therapies.
EXPERT VIDEOS
All video interviews from WCLC 2020
Luis M. Montuenga talks about factors that are impeding the implementation of lowdose computed tomography lung cancer screening at the global level and describes biomarkers/molecular technologies that are promising with respect to early detection of lung cancer. Moreover, he summarizes advantages and drawbacks of pan-cancer ctDNA analysis in liquid biopsy.
Alex Spira highlights the advantages, shortcomings and the future potential of antibodydrug conjugates, the balance between proand anti-inflammatory cytokines within the tumor microenvironment, and the preclinical evidence for targeting inflammatory cytokines in advanced or metastatic non-smallcell lung cancer.
Ming Tsao relates to the innovations of the 5th edition of the WHO classification of lung tumors in terms of additional chapters, new tumor types and grading systems. Additionally, he discusses the use of organoids as potential platforms for drug testing and biomarker validation, as well as miRNAs for early lung cancer detection.
EXPERT VIDEOS
All video interviews from ASH 2020
Steven P. Treon explains about innovative approaches in the treatment of Waldenström’s macroglobulinemia, future aspects and the successful use of BTK inhibition within niche groups of patients with WM, and potential benefits of BTK inhibitors regarding COVID-19 complications.
Jorge Castillo relates to recent developments with respect to follicular lymphoma, multiple myeloma and Waldenström’s macroglobulinemia, current insights into CAR-T cell therapy in the setting of multiple myeloma, and the future of anti-CD38 antibody treatment in patients with Waldenström’s macroglobulinemia.
Alessandra Tedeschi summarizes the results from the MAGNOLIA and iNNOVATE trials, relates to recent advances in the management of marginal zone lymphoma and discusses the effect of the introduction of BTK inhibition on the prognosis of patients with Waldenström’s macroglobulinemia.
Stephen Opat discusses the requirements for treatment-free long-term remission in the setting of CLL and talks about the future of BTK inhibitors and promising combinations in B-cell malignancies in general, as well as the strengths and limitations of immune checkpoint inhibitors.
EXPERT VIDEOS
All video interviews from ESMO Solid Tumors 2020
Andrés Cervantes talks about novel findings obtained in the field of gastric cancer, gastroesophageal junction adenocarcinoma and esophageal cancer as well as developments in hepatocellular carcinoma and investigational immunotherapies that might evolve into new treatment approaches.
Eric Van Cutsem gives an overview of practice-changing results obtained for gastrointestinal cancers including colorectal cancer, gastric cancer and esophageal cancer and describes progress that has recently been made with respect to certain biomarkers.
EXPERT VIDEOS
All video interviews from ESMO Lung Cancer 2020
Tony Mok summarizes insights into the immunotherapeutic management of patients with advanced lung cancer who receive PD-1 inhibitors and relates to aspects of biomarker-based treatment selection, patient prognosis, and new agents that might change the treatment landscape.
Byoung Chul Cho explains about the rationale and outcomes for combined targeted treatment of lung cancer patients with an emphasis on EGFR-mutant disease and describes findings obtained for a first-in-class agent targeting the KRASG212C mutation.
Maarten Lambrecht highlights aspects of radiobiology regarding interactions between radiotherapy and the immune system, non-invasive imaging biomarkers and trial results presented at ESMO 2020 that bear importance from a radiation oncologist’s point of view.
Paul Baas discusses the prognosis and treatment of patients with malignant mesothelioma, relating to combined modality treatment with immune checkpoint inhibitors plus chemotherapy and talks about other immunotherapeutic approaches beyond checkpoint inhibition.
EXPERT VIDEOS
All video interviews from EHA 2020
Shirley D’Sa talks about promising new agents/regimens in the treatment of Waldenström’s macroglobulinemia with respect to efficacy and safety, next-generation BTK inhibitors and recent developments in the management of cold agglutinin disease.
Constantine Tam depicts the most interesting trial results in the field of CLL treatment at the EHA congress and gives an outlook on future treatment options for CLL and mantle cell lymphoma.
Veronique Leblond highlights relevant factors for the selection of treatment in newly diagnosed and relapsed Waldenström’s macroglobulinemia, the connection of BTK inhibitors and MYD88 or CXCR4 mutations and discusses the risk-benefit profile of these drugs.
Peter Hillmen gives an overview of the most relevant treatment strategies in patients with paroxysmal nocturnal hemoglobinuria and further explains the advantages of proximal over terminal complement inhibition.
EXPERT VIDEOS
All video interviews from ASCO 2019
Martin Reck gives an overview on where we are today regarding immunotherapies in early stage NSCLC, discusses recent insights most relevant with respect to immunotherapies in metastatic NSCLC and new data on SCLC.
Marina Garassino on new insights obtained on the optimal use of PD-L1 expression as a biomarker for immunotherapeutic approaches in lung cancer, the significance of tumor mutational burden and what a future “predictive biomarker algorithm” in lung cancer might look like.
Rafal Dziadziuszko explains what we can expect from circulation free DNA as a biomarker in the setting of lung cancer diagnosis and treatment and talks about the clinical significance of circulating free DNA in ALK-positive tumors.
Akito Hata talks about recent insights with regard to the correlation between EGFR mutation status and other biomarkers, the benefit of anti-angiogenic treatment in combination with EGFR-targeted strategies and the ideal treatment sequence with EGFR TKIs.
EXPERT VIDEOS
All video interviews from ELCC 2019
Pilar Garrido gives an overview of the management of patients with stage III NSCLC, novel treatments in stage III disease and recent insights concerning immune modulatory vaccination in patients with NSCLC.
Thomas Newsom-Davis on the treatment algorithm for ALK-positive NSCLC and future developments for patients with ALK/ROS1-positive tumors.
Nir Peled talks about the importance of early detection of lung cancer – especially in poorer countries –, promising biomarkers for the early detection and new insights into the interactions between lung cancer cells and the tumor microenvironment.
Anne-Marie Dingemans explains the importance of chemotherapy in the current management of NSCLC and promising new combinations of chemotherapeutic agents with other drug classes.
EXPERT VIDEOS
All video interviews from ESMO 2019
Filippo de Braud explains what can be achieved with TRK inhibition in TRK-fusion-positive NSCLC, indirectly compares the performance of entrectinib to crizotinib in ROS1-positive disease and shares his opinion on the intracranial activity of entrectinib.
Michael Duruisseaux gives an overview on the role of NRG1 gene fusion in the tumorigenesis of lung cancer, the clinical experience with targeted treatment and the importance of molecular testing with respect to NRG1 fusions.
Stephen Liu on the latest insights in the field of ALK-targeted treatment in lung cancer, a recent update on the clinical evaluation of NRG1-directed therapies, as well as novel molecular targets for lung cancer treatment in the foreseeable future.
Ioannis Metaxas talks about the rationale for the evaluation of lurbinectedin in malignant pleural mesothelioma, the clinical results with lurbinectedin in patients with mesothelioma to date and other areas of lung cancer treatment in which lurbinectedin might prove useful in the future.
EXPERT VIDEOS
All video interviews from ESMO 2018
Sanjay Popat talks about modern chemotherapeutic treatment options for patients with squamous NSCLC, the benefits of combining immunotherapies with chemotherapy and the use of liquid biopsy for metastatic NSCLC in clinical practice today.
Luis Paz-Ares explains new principles of treatment using bifunctional fusion proteins, their advantages compared to the existing therapies and preliminary results in NSCLC patients.
EXPERT VIDEOS
All video interviews from WCLC 2018
Herbert Loong on peculiarities of lung cancer research with a focus on phase I studies.
James Ho talks about novel diagnostic approaches, monitoring of lung cancer patients as well as the potential for the use of antioxidants in lung cancer.
Maximilian Hochmair on the future of combinations of immunotherapies with other drugs as well as his recommendations for treatment sequencing in ALK-positive and EGFR-positive lung cancer.
Vera Hirsh discusses the latest clinical achievements using <em>EGFR</em>-targeted therapy in patients with advanced NSCLC and the role of patient quality of life.
EXPERT VIDEOS
All video interviews from ASCO 2018
Edward Kim talks about the relevance of biomarkers in choosing patients for immunotherapy and the usefulness/pitfalls pf liquid biopsies.
Barbara Melosky talks about ongoing trials that evaluate afatinib/pembrolizumab combination therapy of squamous-cell carcinoma and potential combinations of anti-EGFR agents with anti-angiogenesis drugs.
EXPERT VIDEOS
All video interviews from ASCO 2017
Richard Baird on clinical trial data for treatment of cerebral metastases, including the Cambridge brain mets trial 1 (CamBMT1) phase 1B trial data that he presented at ASCO.
Anna Nowak on malignant mesothelioma: risk factors, prognostic markers, and clinical trial data for mesothelioma treatments to come out of the congress.
Yi-Long Wu, president of the Chinese Society of Clinical Oncology, discusses his society’s collaboration with memo – inOncology, and the approval of afatinib for EGFR+ NSCLC in China.
Maya Gottfried on NSCLC screening and treatment options.
EXPERT VIDEOS
All video interviews from CSCO 2017
Caicun Zhou discusses NSCLC care in China, and the use of molecular targeted agents
Shun Lu discusses the recent clinical trial data for EGFR targeted agents and how this will shape clinical practice, as well as the need for solid clinical trial data revealing how the sequencing of EGFR directed agents affects survival
EXPERT VIDEOS
All video interviews from ESMO 2017
Hossein Borghaei discusses the latest immunotherapeutic treatment options to emerge for lung cancer at the 2017 ESMO congress.
Nicolas Girard on the sequencing of targeted agents against EGFR positive NSCLC, and further considerations for treatment of the disease including side effects and possible combination therapies.
Lecia Sequist on how best to treat oncogene-driven oligometastatic lung cancer, given progression through multiple lines of treatment.
Filippo de Marinis on the latest data from the OAK trial studying the PD-L1 antibody atezolizumab that was presented at the 2017 ESMO congress, including efficacy within particular patient subgroups, and tolerability.
EXPERT VIDEOS
All video interviews from WCLC 2017
David Gandara discusses the latest progress in EGFR, ALK, and checkpoint inhibitor therapies for NSCLC.
Keunchil Park discusses how lung cancer treatments have developed since the advent of chemotherapy, and how best to deliver optimal care to lung cancer patients worldwide, and specifically in South Korea and Japan.
Ramaswamy Govindan discusses the importance of chemotherapy in today’s treatment landscape, and the importance of ethnic genomic differences in mutation rates in lung cancer.
Paul A. Bunn discusses current and future treatment options in lung cancer.
EXPERT VIDEOS
All video interviews from ESMO 2016
Enriqueta Felip on the treatment of RET- and ROS1-rearrangement positive lung cancer.
Martin Reck discusses the management of immunotherapy related adverse events.
Pasi A. Jänne talks chemotherapy, biomarkers, and molecular targeted therapies.
Anders Mellemgaard on anti-angiogenesis treatments
EXPERT VIDEOS
All video interviews from WCLC 2016
Martin Schuler on the current state-of-play for EGFR diagnostic technologies
Johan Vansteenkiste discusses the practical considerations for immunotherapy
Robert Pirker on the hot topics in lung cancer research on the agenda at the IASLC 2017 WCLC congress
Fiona Blackhall on the importance of molecular diagnosis on the diagnosis and follow up of lung cancer
James Chih-Hsin Yang talks TKIs
Videos
Impressions from participants – Preceptorship 2016 Vienna
Participants of the inaugural Springer International Lung Cancer Preceptorship 2016 give their impressions of the meeting.
